XML 49 R28.htm IDEA: XBRL DOCUMENT
v3.23.1

Quarterly Financial Information (Unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2022
Quarterly Financial Information Disclosure [Abstract] |
Quarterly Financial Information (Unaudited) | Quarterly Financial Information (Unaudited) In connection with the preparation of the restated consolidated financial statements included in Note 3, Restatement of Previously Issued Consolidated Financial Statements, the Company also identified an error in the long-lived asset impairment analysis performed in the third quarter of 2022, which resulted in an understatement of impairment loss as discussed below. Impairment of Long-Lived Assets In August 2022, the Company revised its financial outlook, which the Company identified as an indicator of impairment for the Company’s Aarki asset group. In the third quarter of 2022, the Company recorded an impairment loss of $47.6 million on intangible assets related to the Aarki acquisition. The Company subsequently noted additional indicators of impairment during the fourth quarter of 2022, most notably sharp declines in the Company’s stock price and market capitalization near the end of 2022. During the assessment performed as of December 31, 2022, it was determined that there was an error in the Company’s identification of the Aarki asset group in the impairment analysis performed as of August 31, 2022. As a result, the impairment loss in the third quarter of 2022 was understated by $3.6 million in the consolidated statements of operations and comprehensive loss, and the related intangible assets as of September 30, 2022 were overstated in the consolidated balance sheets. This error is incremental to the errors discussed in Note 3 for the understatement of end-user liability, reserve for indirect tax liabilities, and other adjustments which also had impacts to the previously issued 2022, 2021 and 2020 quarterly consolidated financial statements. In connection therewith, the Company has made adjustments to its previously issued 2022, 2021 and 2020 quarterly financial information to correct these errors and other immaterial misstatements for such periods. The following tables for each of the quarters in the years ended December 31, 2022, 2021 and 2020 reflect the quarterly information as filed in the Company’s Quarterly Report on Form 10-Q for the periods ended September 30, 2022, 2021 and 2020, June 30, 2022, 2021 and 2020, and March 31, 2022, 2021 and 2020, as restated for these errors. Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss, Fiscal Year 2022 The following unaudited condensed consolidated statements of operations and comprehensive loss tables present the impacts of the restatement adjustments for the periods ended September 30, 2022, 2021 and 2020, June 30, 2022, 2021 and 2020, and March 31, 2022, 2021 and 2020 (in thousands, except for per share amounts). For the impacts of the restatement adjustments for the statements of operations and comprehensive loss for the year ended December 31, 2021 and 2020, refer to Note 3 - Restatement of Previously Issued Consolidated Financial Statements. The year ended December 31, 2022 was not subject to restatement and is presented in Part 1 of Item 8. Financial Statements.
| Three Months Ended September 30, 2022
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Revenue | $ | 60,255 |  |  | $ | (71) |  |  | $ | (856) |  |  | $ | — |  |  | $ | (112) |  |  | $ | 59,216 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenue | 7,555 |  |  | — |  |  | — |  |  | (245) |  |  | 289 |  |  | 7,599 |
Research and development | 8,354 |  |  | — |  |  | — |  |  | — |  |  | (417) |  |  | 7,937 |
Sales and marketing | 51,773 |  |  | (84) |  |  | — |  |  | (2) |  |  | (207) |  |  | 51,480 |
General and administrative | 20,280 |  |  | — |  |  | 152 |  |  | (21) |  |  | 525 |  |  | 20,936 |
Impairment of goodwill and long-lived assets | 47,581 |  |  | — |  |  | — |  |  | 3,649 |  |  | — |  |  | 51,230 |
Total costs and expenses | 135,543 |  |  | (84) |  |  | 152 |  |  | 3,381 |  |  | 190 |  |  | 139,182 |
Loss from operations | (75,288) |  |  | 13 |  |  | (1,008) |  |  | (3,381) |  |  | (302) |  |  | (79,966) |
Interest expense, net | (3,807) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (3,807) |
Change in fair value of common stock warrant liabilities | (80) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (80) |
Other income, net | 508 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 508 |
Loss before income taxes | (78,667) |  |  | 13 |  |  | (1,008) |  |  | (3,381) |  |  | (302) |  |  | (83,345) |
Benefit for income taxes | (120) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (120) |
Net loss | $ | (78,547) |  |  | $ | 13 |  |  | $ | (1,008) |  |  | $ | (3,381) |  |  | $ | (302) |  |  | $ | (83,225) |
Net loss per share attributable to common stockholders: |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (0.19) |  |  | $ | — |  |  | $ | — |  |  | $ | (0.01) |  |  | $ | — |  |  | $ | (0.20) |
Diluted | $ | (0.19) |  |  | $ | — |  |  | $ | — |  |  | $ | (0.01) |  |  | $ | — |  |  | $ | (0.20) |
Other comprehensive loss: |  |  |  |  |  |  |  |  |  |  |
Change in unrealized loss on available-for-sale investments, net of tax | 139 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 139 |
Total other comprehensive loss | $ | 139 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 139 |
Total comprehensive loss | $ | (78,408) |  |  | $ | 13 |  |  | $ | (1,008) |  |  | $ | (3,381) |  |  | $ | (302) |  |  | $ | (83,086) |
| Three Months Ended June 30, 2022
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Revenue | $ | 73,335 |  |  | $ | (83) |  |  | $ | (1,470) |  |  | $ | — |  |  | $ | (25) |  |  | $ | 71,757 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenue | 9,020 |  |  | — |  |  | — |  |  | — |  |  | (17) |  |  | 9,003 |
Research and development | 18,529 |  |  | — |  |  | — |  |  | — |  |  | (276) |  |  | 18,253 |
Sales and marketing | 73,185 |  |  | 1,053 |  |  | — |  |  | — |  |  | (507) |  |  | 73,731 |
General and administrative | 26,712 |  |  | — |  |  | 184 |  |  | — |  |  | (15) |  |  | 26,881 |
Impairment of goodwill and long-lived assets | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total costs and expenses | 127,446 |  |  | 1,053 |  |  | 184 |  |  | — |  |  | (815) |  |  | 127,868 |
Loss from operations | (54,111) |  |  | (1,136) |  |  | (1,654) |  |  | — |  |  | 790 |  |  | (56,111) |
Interest expense, net | (7,596) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (7,596) |
Change in fair value of common stock warrant liabilities | 1,023 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,023 |
Other expense, net | (82) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (82) |
Loss before income taxes | (60,766) |  |  | (1,136) |  |  | (1,654) |  |  | — |  |  | 790 |  |  | (62,766) |
Benefit for income taxes | (155) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (155) |
Net loss | $ | (60,611) |  |  | $ | (1,136) |  |  | $ | (1,654) |  |  | $ | — |  |  | $ | 790 |  |  | $ | (62,611) |
Net loss per share attributable to common stockholders: (1) |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (0.15) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.16) |
Diluted | $ | (0.15) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.16) |
Other comprehensive loss: |  |  |  |  |  |  |  |  |  |  |
Change in unrealized loss on available-for-sale investments, net of tax | (577) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (577) |
Total other comprehensive loss | $ | (577) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (577) |
Total comprehensive loss | $ | (61,188) |  |  | $ | (1,136) |  |  | $ | (1,654) |  |  | $ | — |  |  | $ | 790 |  |  | $ | (63,188) |
(1) Due to differences in rounding to the nearest cent per basic or diluted share, totals may not equal the sum of the line items.
| Three Months Ended March 31, 2022
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Revenue | $ | 93,438 |  |  | $ | (52) |  |  | $ | (1,435) |  |  | $ | — |  |  | $ | (87) |  |  | $ | 91,864 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenue | 9,265 |  |  | — |  |  | — |  |  | — |  |  | (65) |  |  | 9,200 |
Research and development | 18,653 |  |  | — |  |  | — |  |  | — |  |  | (3) |  |  | 18,650 |
Sales and marketing | 117,332 |  |  | 630 |  |  | — |  |  | — |  |  | (617) |  |  | 117,345 |
General and administrative | 92,792 |  |  | — |  |  | (76) |  |  | — |  |  | 7 |  |  | 92,723 |
Impairment of goodwill and long-lived assets | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total costs and expenses | 238,042 |  |  | 630 |  |  | (76) |  |  | — |  |  | (678) |  |  | 237,918 |
Loss from operations | (144,604) |  |  | (682) |  |  | (1,359) |  |  | — |  |  | 591 |  |  | (146,054) |
Interest expense, net | (8,157) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (8,157) |
Change in fair value of common stock warrant liabilities | 4,462 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 4,462 |
Other expense, net | (27) |  |  | — |  |  | — |  |  | — |  |  | (1) |  |  | (28) |
Loss before income taxes | (148,326) |  |  | (682) |  |  | (1,359) |  |  | — |  |  | 590 |  |  | (149,777) |
Benefit for income taxes | (213) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (213) |
Net loss | $ | (148,113) |  |  | $ | (682) |  |  | $ | (1,359) |  |  | $ | — |  |  | $ | 590 |  |  | $ | (149,564) |
Net loss per share attributable to common stockholders: |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (0.37) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.37) |
Diluted | $ | (0.37) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.37) |
Other comprehensive loss: |  |  |  |  |  |  |  |  |  |  |
Change in unrealized loss on available-for-sale investments, net of tax | (2,046) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (2,046) |
Total other comprehensive loss | $ | (2,046) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (2,046) |
Total comprehensive loss | $ | (150,159) |  |  | $ | (682) |  |  | $ | (1,359) |  |  | $ | — |  |  | $ | 590 |  |  | $ | (151,610) |
Condensed Consolidated Statements of Operations and Comprehensive Loss, Fiscal Year 2021
| Three Months Ended December 31, 2021
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Revenue | $ | 108,849 |  |  | $ | (41) |  |  | $ | (1,114) |  |  | $ | — |  |  | $ | 506 |  |  | $ | 108,200 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenue | 8,422 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 8,422 |
Research and development | 15,433 |  |  | — |  |  | — |  |  | — |  |  | 311 |  |  | 15,744 |
Sales and marketing | 155,080 |  |  | 531 |  |  | — |  |  | — |  |  | (207) |  |  | 155,404 |
General and administrative | 33,934 |  |  | — |  |  | 192 |  |  | — |  |  | 122 |  |  | 34,248 |
Impairment of goodwill and long-lived assets | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total costs and expenses | 212,869 |  |  | 531 |  |  | 192 |  |  | — |  |  | 226 |  |  | 213,818 |
Loss from operations | (104,020) |  |  | (572) |  |  | (1,306) |  |  | — |  |  | 280 |  |  | (105,618) |
Interest expense, net | (1,086) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,086) |
Change in fair value of common stock warrant liabilities | 6,024 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 6,024 |
Other expense, net | (59) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (59) |
Loss before income taxes | (99,141) |  |  | (572) |  |  | (1,306) |  |  | — |  |  | 280 |  |  | (100,739) |
Benefit for income taxes | (170) |  |  | — |  |  | — |  |  | — |  |  | (144) |  |  | (314) |
Net loss | $ | (98,971) |  |  | $ | (572) |  |  | $ | (1,306) |  |  | $ | — |  |  | $ | 424 |  |  | $ | (100,425) |
Net loss per share attributable to common stockholders: |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (0.25) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.25) |
Diluted | $ | (0.25) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.25) |
Other comprehensive loss: |  |  |  |  |  |  |  |  |  |  |
Change in unrealized loss on available-for-sale investments, net of tax | (248) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (248) |
Total other comprehensive loss | $ | (248) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (248) |
Total comprehensive loss | $ | (99,219) |  |  | $ | (572) |  |  | $ | (1,306) |  |  | $ | — |  |  | $ | 424 |  |  | $ | (100,673) |
| Three Months Ended September 30, 2021
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Revenue | $ | 102,072 |  |  | $ | (34) |  |  | $ | (1,008) |  |  | $ | — |  |  | $ | (506) |  |  | $ | 100,524 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenue | 7,647 |  |  | — |  |  | — |  |  | — |  |  | 532 |  |  | 8,179 |
Research and development | 13,162 |  |  | — |  |  | — |  |  | — |  |  | (96) |  |  | 13,066 |
Sales and marketing | 114,531 |  |  | 636 |  |  | — |  |  | — |  |  | (339) |  |  | 114,828 |
General and administrative | 48,376 |  |  | — |  |  | 176 |  |  | — |  |  | (38) |  |  | 48,514 |
Impairment of goodwill and long-lived assets | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total costs and expenses | 183,716 |  |  | 636 |  |  | 176 |  |  | — |  |  | 59 |  |  | 184,587 |
Loss from operations | (81,644) |  |  | (670) |  |  | (1,184) |  |  | — |  |  | (565) |  |  | (84,063) |
Interest expense, net | (87) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (87) |
Change in fair value of common stock warrant liabilities | 113,601 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 113,601 |
Other expense, net | (22) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (22) |
Income before income taxes | 31,848 |  |  | (670) |  |  | (1,184) |  |  | — |  |  | (565) |  |  | 29,429 |
Benefit for income taxes | (18,933) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (18,933) |
Net income | $ | 50,781 |  |  | $ | (670) |  |  | $ | (1,184) |  |  | $ | — |  |  | $ | (565) |  |  | $ | 48,362 |
Net income (loss) loss per share attributable to common stockholders: |  |  |  |  |  |  |  |  |  |  |
Basic | $ | 0.13 |  |  | $ | — |  |  | $ | (0.01) |  |  | $ | — |  |  | $ | — |  |  | $ | 0.12 |
Diluted | $ | (0.16) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.16) |
Other comprehensive loss: |  |  |  |  |  |  |  |  |  |  |
Change in unrealized loss on available-for-sale investments, net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total other comprehensive loss | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Total comprehensive loss | $ | 50,781 |  |  | $ | (670) |  |  | $ | (1,184) |  |  | $ | — |  |  | $ | (565) |  |  | $ | 48,362 |
| Three Months Ended June 30, 2021
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Revenue | $ | 89,491 |  |  | $ | (38) |  |  | $ | (891) |  |  | $ | — |  |  | $ | — |  |  | $ | 88,562 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenue | 4,386 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 4,386 |
Research and development | 10,140 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 10,140 |
Sales and marketing | 99,523 |  |  | 475 |  |  | — |  |  | — |  |  | — |  |  | 99,998 |
General and administrative | 25,432 |  |  | — |  |  | 169 |  |  | — |  |  | — |  |  | 25,601 |
Impairment of goodwill and long-lived assets | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total costs and expenses | 139,481 |  |  | 475 |  |  | 169 |  |  | — |  |  | — |  |  | 140,125 |
Loss from operations | (49,990) |  |  | (513) |  |  | (1,060) |  |  | — |  |  | — |  |  | (51,563) |
Interest expense, net | (25) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (25) |
Change in fair value of common stock warrant liabilities | (29,595) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (29,595) |
Other income, net | 80 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 80 |
Loss before income taxes | (79,530) |  |  | (513) |  |  | (1,060) |  |  | — |  |  | — |  |  | (81,103) |
Provision for income taxes | 65 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 65 |
Net loss | $ | (79,595) |  |  | $ | (513) |  |  | $ | (1,060) |  |  | $ | — |  |  | $ | — |  |  | $ | (81,168) |
Net loss per share attributable to common stockholders: |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (0.21) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.21) |
Diluted | $ | (0.21) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.21) |
Other comprehensive loss: |  |  |  |  |  |  |  |  |  |  |
Change in unrealized loss on available-for-sale investments, net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total other comprehensive loss | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Total comprehensive loss | $ | (79,595) |  |  | $ | (513) |  |  | $ | (1,060) |  |  | $ | — |  |  | $ | — |  |  | $ | (81,168) |
| Three Months Ended March 31, 2021
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Revenue | $ | 83,677 |  |  | $ | (25) |  |  | $ | (784) |  |  | $ | — |  |  | $ | — |  |  | $ | 82,868 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenue | 4,256 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 4,256 |
Research and development | 7,282 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 7,282 |
Sales and marketing | 96,323 |  |  | 138 |  |  | — |  |  | — |  |  | — |  |  | 96,461 |
General and administrative | 27,284 |  |  | — |  |  | 155 |  |  | — |  |  | — |  |  | 27,439 |
Impairment of goodwill and long-lived assets | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total costs and expenses | 135,145 |  |  | 138 |  |  | 155 |  |  | — |  |  | — |  |  | 135,438 |
Loss from operations | (51,468) |  |  | (163) |  |  | (939) |  |  | — |  |  | — |  |  | (52,570) |
Interest expense, net | (24) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (24) |
Change in fair value of common stock warrant liabilities | (2,108) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (2,108) |
Other income, net | 50 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 50 |
Loss before income taxes | (53,550) |  |  | (163) |  |  | (939) |  |  | — |  |  | — |  |  | (54,652) |
Provision for income taxes | 42 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 42 |
Net loss | $ | (53,592) |  |  | $ | (163) |  |  | $ | (939) |  |  | $ | — |  |  | $ | — |  |  | $ | (54,694) |
Net loss per share attributable to common stockholders: |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (0.15) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.15) |
Diluted | $ | (0.16) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.16) |
Other comprehensive loss: |  |  |  |  |  |  |  |  |  |  |
Change in unrealized loss on available-for-sale investments, net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total other comprehensive loss | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Total comprehensive loss | $ | (53,592) |  |  | $ | (163) |  |  | $ | (939) |  |  | $ | — |  |  | $ | — |  |  | $ | (54,694) |
| Three Months Ended December 31, 2020
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Revenue | $ | 67,723 |  |  | $ | (25) |  |  | $ | (321) |  |  | $ | — |  |  | $ | — |  |  | $ | 67,377 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenue | 3,475 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 3,475 |
Research and development | 9,972 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 9,972 |
Sales and marketing | 79,560 |  |  | 1,179 |  |  | — |  |  | — |  |  | — |  |  | 80,739 |
General and administrative | 17,953 |  |  | — |  |  | 53 |  |  | — |  |  | — |  |  | 18,006 |
Impairment of goodwill and long-lived assets | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total costs and expenses | 110,960 |  |  | 1,179 |  |  | 53 |  |  | — |  |  | — |  |  | 112,192 |
Loss from operations | (43,237) |  |  | (1,204) |  |  | (374) |  |  | — |  |  | — |  |  | (44,815) |
Interest expense, net | (28) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (28) |
Change in fair value of common stock warrant liabilities | (23,049) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (23,049) |
Other expense, net | (651) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (651) |
Loss before income taxes | (66,965) |  |  | (1,204) |  |  | (374) |  |  | — |  |  | — |  |  | (68,543) |
Provision for income taxes | 15 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 15 |
Net loss | $ | (66,980) |  |  | $ | (1,204) |  |  | $ | (374) |  |  | $ | — |  |  | $ | — |  |  | $ | (68,558) |
Net loss per share attributable to common stockholders:(1) |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (0.22) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.23) |
Diluted | $ | (0.22) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.23) |
Other comprehensive loss: |  |  |  |  |  |  |  |  |  |  |
Change in unrealized loss on available-for-sale investments, net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total other comprehensive loss | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Total comprehensive loss | $ | (66,980) |  |  | $ | (1,204) |  |  | $ | (374) |  |  | $ | — |  |  | $ | — |  |  | $ | (68,558) |
(1) Due to differences in rounding to the nearest cent per basic or diluted share, totals may not equal the sum of the line items.
| Three Months Ended September 30, 2020
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Revenue | $ | 59,955 |  |  | $ | (19) |  |  | $ | (252) |  |  | $ | — |  |  | $ | — |  |  | $ | 59,684 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenue | 3,102 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 3,102 |
Research and development | 4,369 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 4,369 |
Sales and marketing | 73,187 |  |  | 390 |  |  | — |  |  | — |  |  | — |  |  | 73,577 |
General and administrative | 7,861 |  |  | — |  |  | 44 |  |  | — |  |  | — |  |  | 7,905 |
Impairment of goodwill and long-lived assets | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total costs and expenses | 88,519 |  |  | 390 |  |  | 44 |  |  | — |  |  | — |  |  | 88,953 |
Loss from operations | (28,564) |  |  | (409) |  |  | (296) |  |  | — |  |  | — |  |  | (29,269) |
Interest expense, net | (24) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (24) |
Change in fair value of common stock warrant liabilities | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Other expense, net | (14,216) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (14,216) |
Loss before income taxes | (42,804) |  |  | (409) |  |  | (296) |  |  | — |  |  | — |  |  | (43,509) |
Provision for income taxes | 47 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 47 |
Net loss | $ | (42,851) |  |  | $ | (409) |  |  | $ | (296) |  |  | $ | — |  |  | $ | — |  |  | $ | (43,556) |
Net loss per share attributable to common stockholders:(1) |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (0.14) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.15) |
Diluted | $ | (0.14) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.15) |
Other comprehensive loss: |  |  |  |  |  |  |  |  |  |  |
Change in unrealized loss on available-for-sale investments, net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total other comprehensive loss | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Total comprehensive loss | $ | (42,851) |  |  | $ | (409) |  |  | $ | (296) |  |  | $ | — |  |  | $ | — |  |  | $ | (43,556) |
(1) Due to differences in rounding to the nearest cent per basic or diluted share, totals may not equal the sum of the line items.
| Three Months Ended June 30, 2020
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Revenue | $ | 58,878 |  |  | $ | (24) |  |  | $ | (240) |  |  | $ | — |  |  | $ | — |  |  | $ | 58,614 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenue | 2,937 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 2,937 |
Research and development | 4,518 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 4,518 |
Sales and marketing | 52,369 |  |  | 416 |  |  | — |  |  | — |  |  | — |  |  | 52,785 |
General and administrative | 11,642 |  |  | — |  |  | 44 |  |  | — |  |  | — |  |  | 11,686 |
Impairment of goodwill and long-lived assets | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total costs and expenses | 71,466 |  |  | 416 |  |  | 44 |  |  | — |  |  | — |  |  | 71,926 |
Loss from operations | (12,588) |  |  | (440) |  |  | (284) |  |  | — |  |  | — |  |  | (13,312) |
Interest expense, net | (957) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (957) |
Change in fair value of common stock warrant liabilities | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Other expense, net | (6,584) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (6,584) |
Loss before income taxes | (20,129) |  |  | (440) |  |  | (284) |  |  | — |  |  | — |  |  | (20,853) |
Provision for income taxes | 28 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 28 |
Net loss | $ | (20,157) |  |  | $ | (440) |  |  | $ | (284) |  |  | $ | — |  |  | $ | — |  |  | $ | (20,881) |
Net loss per share attributable to common stockholders: |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (0.07) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.07) |
Diluted | $ | (0.07) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.07) |
Other comprehensive loss: |  |  |  |  |  |  |  |  |  |  |
Change in unrealized loss on available-for-sale investments, net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total other comprehensive loss | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Total comprehensive loss | $ | (20,157) |  |  | $ | (440) |  |  | $ | (284) |  |  | $ | — |  |  | $ | — |  |  | $ | (20,881) |
| Three Months Ended March 31, 2020
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Revenue | $ | 43,559 |  |  | $ | (17) |  |  | $ | (170) |  |  | $ | — |  |  | $ | — |  |  | $ | 43,372 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenue | 2,767 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 2,767 |
Research and development | 4,366 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 4,366 |
Sales and marketing | 46,825 |  |  | 343 |  |  | — |  |  | — |  |  | — |  |  | 47,168 |
General and administrative | 4,833 |  |  | — |  |  | 32 |  |  | — |  |  | — |  |  | 4,865 |
Impairment of goodwill and long-lived assets | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total costs and expenses | 58,791 |  |  | 343 |  |  | 32 |  |  | — |  |  | — |  |  | 59,166 |
Loss from operations | (15,232) |  |  | (360) |  |  | (202) |  |  | — |  |  | — |  |  | (15,794) |
Interest expense, net | (316) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (316) |
Change in fair value of common stock warrant liabilities | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Other income, net | 51 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 51 |
Loss before income taxes | (15,497) |  |  | (360) |  |  | (202) |  |  | — |  |  | — |  |  | (16,059) |
Provision for income taxes | 25 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 25 |
Net loss | $ | (15,522) |  |  | $ | (360) |  |  | $ | (202) |  |  | $ | — |  |  | $ | — |  |  | $ | (16,084) |
Net loss per share attributable to common stockholders: |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (0.06) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.06) |
Diluted | $ | (0.06) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (0.06) |
Other comprehensive loss: |  |  |  |  |  |  |  |  |  |  |
Change in unrealized loss on available-for-sale investments, net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total other comprehensive loss | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Total comprehensive loss | $ | (15,522) |  |  | $ | (360) |  |  | $ | (202) |  |  | $ | — |  |  | $ | — |  |  | $ | (16,084) |
Condensed Consolidated Balance Sheets The following unaudited condensed consolidated balance sheet tables present the impacts of the restatement adjustments as of the periods ended September 30, 2022 and 2021, June 30, 2022 and 2021, and March 31, 2022 and 2021. For the impacts of the restatement adjustments for the consolidated balance sheets as of December 31, 2021 refer to Note 3, Restatement of Previously Issued Financial Statements. The period ended December 31, 2022 was not subject to restatement and is presented in Part 1 of Item 8. Financial Statements.
| As of September 30, 2022
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Accounts receivable, net | $ | 9,001 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (829) |  |  | $ | 8,172 |
Total current assets | 492,446 |  |  | — |  |  | — |  |  | — |  |  | (829) |  |  | 491,617 |
Property and equipment, net | 7,247 |  |  | — |  |  | — |  |  | (2,466) |  |  | — |  |  | 4,781 |
Operating lease right-of-use assets, net | 13,366 |  |  | — |  |  | — |  |  | (653) |  |  | — |  |  | 12,713 |
Intangible assets, net | 20,289 |  |  | — |  |  | — |  |  | (264) |  |  | — |  |  | 20,025 |
Goodwill | 86,436 |  |  | — |  |  | — |  |  | — |  |  | (973) |  |  | 85,463 |
Total assets | 772,414 |  |  | — |  |  | — |  |  | (3,383) |  |  | (1,802) |  |  | 767,229 |
Other current liabilities | 45,890 |  |  | 9,972 |  |  | 10,254 |  |  | — |  |  | (2,394) |  |  | 63,722 |
Total current liabilities | 53,222 |  |  | 9,972 |  |  | 10,254 |  |  | — |  |  | (2,394) |  |  | 71,054 |
Other long-term liabilities | 1,687 |  |  | — |  |  | — |  |  | — |  |  | (144) |  |  | 1,543 |
Total liabilities | 340,113 |  |  | 9,972 |  |  | 10,254 |  |  | — |  |  | (2,538) |  |  | 357,801 |
Additional paid-in capital | 1,141,955 |  |  | — |  |  | — |  |  | — |  |  | (199) |  |  | 1,141,756 |
Accumulated deficit | (706,963) |  |  | (9,972) |  |  | (10,254) |  |  | (3,383) |  |  | 935 |  |  | (729,637) |
Total stockholders’ equity | 432,301 |  |  | (9,972) |  |  | (10,254) |  |  | (3,383) |  |  | 736 |  |  | 409,428 |
Total liabilities and stockholders’ equity | $ | 772,414 |  |  | $ | — |  |  | $ | — |  |  | $ | (3,383) |  |  | $ | (1,802) |  |  | $ | 767,229 |
| As of June 30, 2022
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Accounts receivable, net | $ | 10,630 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (391) |  |  | $ | 10,239 |
Total current assets | 502,512 |  |  | — |  |  | — |  |  | — |  |  | (391) |  |  | 502,121 |
Goodwill | 86,436 |  |  | — |  |  | — |  |  | — |  |  | (973) |  |  | 85,463 |
Total assets | 858,903 |  |  | — |  |  | — |  |  | — |  |  | (1,364) |  |  | 857,539 |
Other current liabilities | 54,838 |  |  | 9,985 |  |  | 9,246 |  |  | — |  |  | (2,023) |  |  | 72,046 |
Total current liabilities | 58,379 |  |  | 9,985 |  |  | 9,246 |  |  | — |  |  | (2,023) |  |  | 75,587 |
Other long-term liabilities | 1,180 |  |  | — |  |  | — |  |  | — |  |  | (144) |  |  | 1,036 |
Total liabilities | 354,016 |  |  | 9,985 |  |  | 9,246 |  |  | — |  |  | (2,167) |  |  | 371,080 |
Additional paid-in capital | 1,136,133 |  |  | — |  |  | — |  |  | — |  |  | (435) |  |  | 1,135,698 |
Accumulated deficit | (628,416) |  |  | (9,985) |  |  | (9,246) |  |  | — |  |  | 1,238 |  |  | (646,409) |
Total stockholders’ equity | 504,887 |  |  | (9,985) |  |  | (9,246) |  |  | — |  |  | 803 |  |  | 486,459 |
Total liabilities and stockholders’ equity | $ | 858,903 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (1,364) |  |  | $ | 857,539 |
| As of March 31, 2022
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Accounts receivable, net | $ | 13,230 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (303) |  |  | $ | 12,927 |
Total current assets | 519,321 |  |  | — |  |  | — |  |  | — |  |  | (303) |  |  | 519,018 |
Goodwill | 86,436 |  |  | — |  |  | — |  |  | — |  |  | (973) |  |  | 85,463 |
Total assets | 932,536 |  |  | — |  |  | — |  |  | — |  |  | (1,276) |  |  | 931,260 |
Other current liabilities | 57,607 |  |  | 8,849 |  |  | 7,591 |  |  | — |  |  | (1,533) |  |  | 72,514 |
Total current liabilities | 72,917 |  |  | 8,849 |  |  | 7,591 |  |  | — |  |  | (1,533) |  |  | 87,824 |
Long-term debt, non-current | 279,713 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 279,713 |
Other long-term liabilities | 13,238 |  |  | — |  |  | — |  |  | — |  |  | (144) |  |  | 13,094 |
Total liabilities | 380,898 |  |  | 8,849 |  |  | 7,591 |  |  | — |  |  | (1,677) |  |  | 395,661 |
Additional paid-in capital | 1,121,697 |  |  | — |  |  | — |  |  | — |  |  | (46) |  |  | 1,121,651 |
Accumulated deficit | (567,805) |  |  | (8,849) |  |  | (7,591) |  |  | — |  |  | 447 |  |  | (583,798) |
Total stockholders’ equity | 551,638 |  |  | (8,849) |  |  | (7,591) |  |  | — |  |  | 401 |  |  | 535,599 |
Total liabilities and stockholders’ equity | $ | 932,536 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (1,276) |  |  | $ | 931,260 |
Condensed Consolidated Balance Sheets, Fiscal year 2021
| As of September 30, 2021
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Accounts receivable, net | $ | 12,725 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (2,039) |  |  | $ | 10,686 |
Total current assets | 570,342 |  |  | — |  |  | — |  |  | — |  |  | (2,039) |  |  | 568,303 |
Goodwill | 87,230 |  |  | — |  |  | — |  |  | — |  |  | (973) |  |  | 86,257 |
Total assets | 811,132 |  |  | — |  |  | — |  |  | — |  |  | (3,012) |  |  | 808,120 |
Accounts payable | 10,047 |  |  | — |  |  | — |  |  | — |  |  | (1,137) |  |  | 8,910 |
Other current liabilities | 70,157 |  |  | 7,596 |  |  | 4,926 |  |  | — |  |  | (1,310) |  |  | 81,369 |
Total current liabilities | 80,204 |  |  | 7,596 |  |  | 4,926 |  |  | — |  |  | (2,447) |  |  | 90,279 |
Total liabilities | 106,796 |  |  | 7,596 |  |  | 4,926 |  |  | — |  |  | (2,447) |  |  | 116,871 |
Accumulated deficit | (320,721) |  |  | (7,596) |  |  | (4,926) |  |  | — |  |  | (565) |  |  | (333,808) |
Total stockholders’ equity | 704,336 |  |  | (7,596) |  |  | (4,926) |  |  | — |  |  | (565) |  |  | 691,249 |
Total liabilities and stockholders’ equity | $ | 811,132 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (3,012) |  |  | $ | 808,120 |
| As of June 30, 2021
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Other current liabilities | $ | 35,531 |  |  | $ | 6,926 |  |  | $ | 3,743 |  |  | $ | — |  |  | $ | — |  |  | $ | 46,200 |
Total current liabilities | 124,934 |  |  | 6,926 |  |  | 3,743 |  |  | — |  |  | — |  |  | 135,603 |
Total liabilities | 185,646 |  |  | 6,926 |  |  | 3,743 |  |  | — |  |  | — |  |  | 196,315 |
Accumulated deficit | (371,502) |  |  | (6,926) |  |  | (3,743) |  |  | — |  |  | — |  |  | (382,171) |
Total stockholders’ equity | $ | 534,812 |  |  | $ | (6,926) |  |  | $ | (3,743) |  |  | $ | — |  |  | $ | — |  |  | $ | 524,143 |
| As of March 31, 2021
| As Reported |  | End-User Liability |  | Indirect Taxes |  | Impairment |  | Other Adjustments |  | As Restated
Other current liabilities | $ | 29,860 |  |  | $ | 6,413 |  |  | $ | 2,682 |  |  | $ | — |  |  | $ | — |  |  | $ | 38,955 |
Total current liabilities | 40,098 |  |  | 6,413 |  |  | 2,682 |  |  | — |  |  | — |  |  | 49,193 |
Total liabilities | 152,512 |  |  | 6,413 |  |  | 2,682 |  |  | — |  |  | — |  |  | 161,607 |
Accumulated deficit | (291,907) |  |  | (6,413) |  |  | (2,682) |  |  | — |  |  | — |  |  | (301,002) |
Total stockholders’ equity | $ | 588,911 |  |  | $ | (6,413) |  |  | $ | (2,682) |  |  | $ | — |  |  | $ | — |  |  | $ | 579,816 |

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI https://asc.fasb.org/topic&trid=2126967 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1B -URI https://asc.fasb.org/extlink&oid=126900988&loc=SL124452896-108306 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration